Insights from 2024 WCLC


 

WCLC 2024 Insights: The Global TRUST-II Study - Efficacy & Safety of Taletrectinib in Patients With ROS1+ NSCLC

21 views
October 11, 2024
Comments 0
Login to view comments. Click here to Login